The finding that TBAG4 possesses a promising antiproliferative activity against breast cancer cells and is able to bind efficiently with NCL is an unprecedented result that represents a significant advancement for the design of TBAG4 analogs endowed with NCL-mediated antiproliferative [18] and antiviral properties [24,30]. This evidence concerns the gene NUCLEOLIN and breast carcinoma.